A Form 4 filed on September 3, 2026 discloses that James E. Davis, CEO and President of Quest Diagnostics Inc (NYSE:DGX), sold 10,000 shares of common stock on September 1, 2026 pursuant to a pre-established Rule 10b5-1 sales plan.

Key Highlights

  • Reporting person: James E. Davis, CEO and President of Quest Diagnostics Inc, also identified as a Director.
  • Transaction: 10,000 shares of Common Stock disposed of (transaction code S) on September 1, 2026.
  • Sale price: $242.72 per share, as reported in the filing.
  • Remaining ownership: 122,423 shares of Common Stock held directly following the transaction.
  • 10b5-1 plan: The sale was effected pursuant to a Rule 10b5-1 sales plan previously adopted by the reporting person.
  • Filing signed: Sean D. Mersten, Attorney in Fact for James E. Davis, signed the form on September 3, 2026.

Quest Diagnostics CEO Davis Reports Share Sale Under Pre-Planned Trading Program

According to the filing, James E. Davis, who serves as CEO and President and is also listed as a Director of Quest Diagnostics Inc, disposed of 10,000 shares of the company's Common Stock on September 1, 2026. The shares were sold at a price of $242.72 each. The filing indicates this is a direct ownership position, and the transaction code recorded is "S," indicating a sale.

The filing discloses that the transaction was carried out under a Rule 10b5-1 sales plan that Davis had previously adopted. As footnote 1 of the filing states, "This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person." Following this transaction, the filing reports that Davis directly holds 122,423 shares of Common Stock.

No derivative securities transactions were reported in Table II of the filing. The form was filed by one reporting person and was submitted to the SEC on September 3, 2026, with Sean D. Mersten, Attorney in Fact for James E. Davis, signing on that date. The filing also notes that the box indicating the transaction was made pursuant to a Rule 10b5-1(c) plan was checked.

What Was Disclosed

Quest Diagnostics CEO and President James E. Davis reported the sale of 10,000 shares of Common Stock at $242.72 per share on September 1, 2026, conducted under a pre-adopted Rule 10b5-1 plan. His directly held beneficial ownership following the transaction stands at 122,423 shares, according to the filing.